← 返回前沿论文

利用公开转录组 RNA-seq 数据集的 meta 分析描绘直肠癌新辅助治疗反应特征

英文原题:Profiling neoadjuvant therapy response in rectal cancer using meta-analysis of publicly available transcriptomic RNA-seq datasets.

查看英文原题

Profiling neoadjuvant therapy response in rectal cancer using meta-analysis of publicly available transcriptomic RNA-seq datasets.

PubMed 2026/09/07(内容时间) Mol Oncol Q2 · IF 4.5(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

新辅助放化疗后行全直肠系膜切除术是局部晚期直肠癌的标准治疗方案,但治疗反应存在差异,现有标志物尚不充分。本研究整合公开的bulk RNA-seq数据,以识别治疗反应的预测特征。TRIM54和PABPC4在应答组中上调,而ADSS1和MGAT1在非应答组中上调。ARMC2被鉴定为预测性生物标志物,在病理完全缓解中上调。应答组显示NK细胞和CD4+淋巴细胞富集,而免疫前体与不良预后相关。转录因子分析显示,非应答组中SP1和NFKB激活,应答组中TCF15激活。SMAD3和RDXANK与完全消退相关,而MYC在不完全消退中占主导地位。这些发现为治疗反应背后的机制提供了见解。据我们所知,这是首个使用高通量测序数据的meta分析,为未来直肠癌研究提供了有价值的起点。

展开英文摘要原文

Neoadjuvant chemoradiotherapy followed by total mesorectal excision is standard for locally advanced rectal cancer, but response varies and current markers are insufficient.

This study integrates public bulk RNA-seq data to identify predictive features of response. TRIM54 and PABPC4 were upregulated in the responder group, while ADSS1 and MGAT1 were upregulated in the non-responder group. ARMC2 was identified as a predictive biomarker upregulated in pathological complete response.

Responder group showed enrichment of NK cells and CD4+ lymphocytes, while immune precursors were linked to poor outcome. Transcription factor analysis revealed SP1 and NFKB activations in the non-responder group and TCF15 in the responder group. SMAD3 and RDXANK were associated with complete regression, while MYC was dominant in incomplete regression.

These findings provide insight into mechanisms underlying therapy response. To our knowledge, this is the first meta-analysis using high-throughput sequencing data, providing a valuable starting point for future rectal cancer research.

论文信息

作者
Stanojevic A、Stroggilos R、Marinkovic M、Djuric A、Stojanovic-Rundic S、Jankovic R、Castellvi-Bel S、Fijneman RJA
单位
Department of Experimental Oncology, Institute for Oncology and Radiology of Serbia (IORS), Belgrade, Serbia.Serbia
期刊
Molecular oncology2026 Sep 7
原文标识
PubMed 42703166 · DOI 10.1002/1878-0261.70324